Immunoglobulin G - Biotest AG

Drug Profile

Immunoglobulin G - Biotest AG

Alternative Names: BT 090; BT 681; Immunoglobulin liquid intravenous - Biotest AG; Intratect 10%; Intratect 100g/L; Intratect 5%; Intratect 50g/L; IVIG - Biotest AG

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biotest AG
  • Class Immunoglobulin isotypes
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Agammaglobulinaemia; Guillain-Barre syndrome; Immune thrombocytopenic purpura; Immunodeficiency disorders; Mucocutaneous lymph node syndrome
  • Phase III Pain

Most Recent Events

  • 06 Jun 2017 No recent reports on development identified - Registered for Immunodeficiency disorders in Vietnam (IV,liquid,10%)
  • 01 Jan 2013 Merz Pharma acquires marketing rights for Intratect® in Russia, from Biotest AG
  • 24 Oct 2012 Registered for Agammaglobulinaemia in European Union (10% solution) (IV) - decentralised procedure with Germany as Reference Member State; 18 other countries involved in procedure
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top